Sign in with Google
BrainStorm Cell Therapeutics (BCLI) - Fundamentals Update 09042025
SUMMARY
- BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI) develops NurOwn® stem cell therapy for NDDs – BCLI’s first target is ALS (MND/Lou Gehrig’s).
- Recent micro capitalization and patent development buy time for non-dilutive funding to be secured.
- BCLI’s Nasdaq compliance for minimum price was regained in late Oct 24, which helps maintain capital access.
Related Insights
More »Loading
Trending Collections
More »Trending Insights
More »- [Japan M&A] Toyota Inds (6201) Proposed Takeover - It Looks Bad, and It's Worse Than It Looks
- Toyota Industries (6201 JP): After a High, Comes the Low of a Takeunder
- TIP Customized Taiwan Select High Dividend Index Rebalance: 22 Changes as Expected
- Mayne Disagrees With Cosette On MAC
- Biggest One Day Move in Higher Share Performance YTD in 2025 for Major Korean Holdcos Today - Why?
Top Unpaywalled Insights
More »- VEON US: Pakistan Towers Sale Frees Capital for Digital Growth in Core Market Ahead of Ukraine IPO
- Advanced Look: Navigating the New Macro Landscape Through Quantitative Alpha Generation Strategies
- [IO Technicals 2025/22] Bearish Momentum Strengthens
- Texas Power Play: Grid Sovereignty, Bitcoin, and the Future of AI
- Overview #27 – The Big Beautiful Tragi-Comedy Continues
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
x